Suppr超能文献

KDM1A驱动的RNF81下调通过KLF4去稳定化促进胃癌进展。

KDM1A-driven RNF81 downregulation promotes gastric cancer progression via KLF4 destabilization.

作者信息

Wang Feng, Hao Po, Pu Yongli, He Xiao, He Qing, Cui Hongjuan, Jiang Suting

机构信息

Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, China.

Chongqing Engineering Research Center of Antitumor Natural Drugs, Chongqing Three Gorges Medical College, Chongqing, China.

出版信息

Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03549-z.

Abstract

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, especially in East Asia, with a low 5-year survival rate due to late-stage diagnosis. Identifying molecular mechanisms that regulate GC progression is critical for improving clinical outcomes. RNF81, a member of the tripartite motif (TRIM) family, has demonstrated diverse roles in various cancers. In this study, we uncover its tumor-suppressive function in GC through novel regulatory pathways. Analysis of clinical data and tissue microarrays revealed that RNF81 expression is significantly downregulated in GC tissues and positively correlates with patient survival. Mechanistically, we identified lysine demethylase KDM1A as a key repressor of RNF81 expression. KDM1A recruits transcription factor E2F1 to form a transcriptional repressor complex, reducing H3K4me1 and H3K4me2 levels at the RNF81 promoter. Functional studies showed that RNF81 stabilizes the tumor suppressor KLF4 by binding through its SPRY domain, thereby inhibiting KLF4 ubiquitination and degradation. Overexpression of RNF81 suppressed GC cell proliferation, migration, and invasion in vitro and reduced tumor growth in vivo, effects that were partially rescued by KLF4 knockdown. These findings reveal a novel KDM1A-RNF81-KLF4 regulatory axis in GC and highlight RNF81 as a potential therapeutic target for GC treatment. Targeting this pathway may offer promising strategies to improve outcomes for GC patients.

摘要

胃癌(GC)是全球癌症相关死亡的主要原因,尤其是在东亚地区,由于诊断较晚,其5年生存率较低。确定调节胃癌进展的分子机制对于改善临床结果至关重要。RNF81是三聚体基序(TRIM)家族的成员,已在多种癌症中表现出多种作用。在本研究中,我们通过新的调控途径揭示了其在胃癌中的肿瘤抑制功能。临床数据和组织芯片分析显示,RNF81在胃癌组织中的表达显著下调,且与患者生存率呈正相关。机制上,我们确定赖氨酸去甲基化酶KDM1A是RNF81表达的关键抑制因子。KDM1A招募转录因子E2F1形成转录抑制复合物,降低RNF81启动子处的H3K4me1和H3K4me2水平。功能研究表明,RNF81通过其SPRY结构域结合来稳定肿瘤抑制因子KLF4,从而抑制KLF4的泛素化和降解。RNF81的过表达在体外抑制了胃癌细胞的增殖、迁移和侵袭,并在体内减少了肿瘤生长,KLF4敲低部分挽救了这些作用。这些发现揭示了胃癌中一种新的KDM1A-RNF81-KLF4调控轴,并突出了RNF81作为胃癌治疗潜在靶点的地位。针对这一途径可能为改善胃癌患者的预后提供有前景的策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验